ArticleNeuropsychiatric disease and treatment2013
Pregabalin for the treatment of generalized anxiety disorder: an update.
Article in Neuropsychiatric disease and treatment, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Gabapentin and pregabalin in bipolar disorder, anxiety states, and insomnia: Systematic review, meta-analysis, and rationale.Molecular psychiatry · 2022Pooled it
- Can Long-Term Pharmacotherapy Prevent Relapses in Generalized Anxiety Disorder? A Systematic Review.Clinical drug investigation · 2017Pooled it
- The German guidelines for the treatment of anxiety disorders.European archives of psychiatry and clinical neuroscience · 2015Pooled it
- No Abuse Potential of Silexan in Healthy Recreational Drug Users: A Randomized Controlled Trial.The international journal of neuropsychopharmacology · 2021Trial
- Effects of oral premedication with tramadol, pregabalin or clonidine on shivering after spinal anaesthesia in patients undergoing hysteroscopic procedures.Anaesthesiology intensive therapy · 2020Trial
- Gabapentinoids-duloxetine combination therapy for chronic pain: A mechanism oriented rational to bridge theoretical knowledge and real life setting.British journal of clinical pharmacology · 2026Review
- Pregabalin Depresses Cerebellar Parallel Fiber-Purkinje Cell Synaptic Transmission by Modulating Glun2a-Containing Nmda Receptors in Mice In Vitro.International journal of molecular sciences · 2026Article
- Chronic random sleep deprivation causes prolonged pain hypersensitivity via the anterior cingulate cortex.iScience · 2026Article
- Sleep-related painful erection, erectile dysfunction and psychological distress.Frontiers in psychiatry · 2026Article
- Unlocking Novel Therapeutic Potential of Angiotensin II Receptor Blockers.International journal of molecular sciences · 2025Review
- Article
- How pharmacology can aid in the diagnosis of mental disorders.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Low Dose Pregabalin Improves Gastrointestinal Symptoms of Crohn's Disease.Case reports in gastrointestinal medicine · 2024Article
- Prescribing Trends of Antiseizure Drugs in Women Veterans With Epilepsy.Military medicine · 2023Article
- Comparing the efficacy of electronic cognitive behavioral therapy to medication and combination therapy for generalized anxiety disorder: a quasi-experimental clinical trial.Frontiers in psychiatry · 2023Article
- Chemometrically Assisted Optimization of Pregabalin Fluorescent Derivatization Reaction with a Novel Xanthone Analogue and Validation of the Method for the Determination of Pregabalin in Bulk via a Plate Reader.Molecules (Basel, Switzerland) · 2022Article
- The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond.CNS drugs · 2021Review
- Pharmacotherapy for Anxiety Disorders: From First-Line Options to Treatment Resistance.Focus (American Psychiatric Publishing) · 2021Article
- Efficacy of a Single Dose of Pregabalin on Signs of Anxiety in Cats During Transportation-A Pilot Study.Frontiers in veterinary science · 2021Article
- Anticonvulsant and antipsychotic medications in the pharmacotherapy of panic disorder: a structured review.Therapeutic advances in psychopharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A PREVIOUS REVIEW SUMMARIZED WHAT WAS THEN KNOWN ABOUT THE POTENTIAL ROLE OF PREGABALIN IN THE TREATMENT OF PATIENTS WITH GENERALIZED ANXIETY DISORDER (GAD): this review provides an update on its pharmacological properties and presumed mechanism of action, the liability for abuse, and efficacy and tolerability in patients with GAD. Pregabalin has a similar molecular structure to the inhibitory neurotransmitter gamma amino butyric acid (GABA) but its mechanism of action does not appear to be mediated through effects on GABA. Instead, its anxiolytic effects may arise through high-affinity binding to the alpha-2-delta sub-unit of the P/Q type voltage-gated calcium channel in "over-excited" presynaptic neurons, thereby reducing the release of excitatory neurotransmitters such as glutamate. The findings of randomized controlled trials and meta-analyses together indicate that pregabalin is efficacious in both acute treatment and relapse prevention in GAD, with some evidence of an early onset of effect, and broad efficacy in reducing the severity of psychological and physical symptoms of anxiety. It also has efficacy as an augmenting agent after non-response to antidepressant treatment in GAD. Continuing vigilance is needed in assessing its potential abuse liability but the tolerability profile of pregabalin may confer some advantages over other pharmacological treatments in the short term for treatment in patients with GAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.